Literature DB >> 33538103

Optogenetic brain-stimulation reward: A new procedure to re-evaluate the rewarding versus aversive effects of cannabinoids in dopamine transporter-Cre mice.

Bree A Humburg1, Chloe J Jordan1, Hai-Ying Zhang1, Hui Shen2, Xiao Han1, Guo-Hua Bi1, Briana Hempel1, Ewa Galaj1, Michael H Baumann3, Zheng-Xiong Xi1.   

Abstract

Despite extensive research, the rewarding effects of cannabinoids are still debated. Here, we used a newly established animal procedure called optogenetic intracranial self-stimulation (ICSS) (oICSS) to re-examine the abuse potential of cannabinoids in mice. A specific adeno-associated viral vector carrying a channelrhodopsin gene was microinjected into the ventral tegmental area (VTA) to express light-sensitive channelrhodopsin in dopamine (DA) neurons of transgenic dopamine transporter (DAT)-Cre mice. Optogenetic stimulation of VTA DA neurons was highly reinforcing and produced a classical "sigmoidal"-shaped stimulation-response curve dependent upon the laser pulse frequency. Systemic administration of cocaine dose-dependently enhanced oICSS and shifted stimulation-response curves upward, in a way similar to previously observed effects of cocaine on electrical ICSS. In contrast, Δ9 -tetrahydrocannabinol (Δ9 -THC), but not cannabidiol, dose-dependently decreased oICSS responding and shifted oICSS curves downward. WIN55,212-2 and ACEA, two synthetic cannabinoids often used in laboratory settings, also produced dose-dependent reductions in oICSS. We then examined several new synthetic cannabinoids, which are used recreationally. XLR-11 produced a cocaine-like increase, AM-2201 produced a Δ9 -THC-like reduction, while 5F-AMB had no effect on oICSS responding. Immunohistochemistry and RNAscope in situ hybridization assays indicated that CB1 Rs are expressed mainly in VTA GABA and glutamate neurons, while CB2 Rs are expressed mainly in VTA DA neurons. Together, these findings suggest that most cannabinoids are not reward enhancing, but rather reward attenuating or aversive in mice. Activation of CB1 R and/or CB2 R in different populations of neurons in the brain may underlie the observed actions. Published 2021. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  WIN55,212-2; brain-stimulation reward; cannabinoids; cocaine; dopamine; intracranial self-stimulation; optogenetics; ventral tegmental area; Δ9-THC

Mesh:

Substances:

Year:  2021        PMID: 33538103      PMCID: PMC9308103          DOI: 10.1111/adb.13005

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.093


  70 in total

1.  Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice.

Authors:  Hai-Ying Zhang; Ming Gao; Qing-Rong Liu; Guo-Hua Bi; Xia Li; Hong-Ju Yang; Eliot L Gardner; Jie Wu; Zheng-Xiong Xi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-03       Impact factor: 11.205

Review 2.  Intracranial self-stimulation to evaluate abuse potential of drugs.

Authors:  S Stevens Negus; Laurence L Miller
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

3.  SR141716A, a potent and selective antagonist of the brain cannabinoid receptor.

Authors:  M Rinaldi-Carmona; F Barth; M Héaulme; D Shire; B Calandra; C Congy; S Martinez; J Maruani; G Néliat; D Caput
Journal:  FEBS Lett       Date:  1994-08-22       Impact factor: 4.124

Review 4.  Optogenetic modulation of neural circuits that underlie reward seeking.

Authors:  Garret D Stuber; Jonathan P Britt; Antonello Bonci
Journal:  Biol Psychiatry       Date:  2011-12-22       Impact factor: 13.382

5.  Withdrawal from chronic cocaine administration induces deficits in brain reward function in C57BL/6J mice.

Authors:  Astrid K Stoker; Athina Markou
Journal:  Behav Brain Res       Date:  2011-05-05       Impact factor: 3.332

6.  Effects of endocannabinoid neurotransmission modulators on brain stimulation reward.

Authors:  Styliani Vlachou; George G Nomikos; George Panagis
Journal:  Psychopharmacology (Berl)       Date:  2006-09-05       Impact factor: 4.530

Review 7.  Dopamine and reward: the anhedonia hypothesis 30 years on.

Authors:  Roy A Wise
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

Review 8.  Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.

Authors:  Ewa Galaj; Zheng-Xiong Xi
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

9.  Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response.

Authors:  D Raft; J Gregg; J Ghia; L Harris
Journal:  Clin Pharmacol Ther       Date:  1977-01       Impact factor: 6.875

10.  Sex differences in the self-administration of cannabinoids and other drugs of abuse.

Authors:  Liana Fattore; Paola Fadda; Walter Fratta
Journal:  Psychoneuroendocrinology       Date:  2009-12       Impact factor: 4.905

View more
  3 in total

1.  Therapeutic potential of PIMSR, a novel CB1 receptor neutral antagonist, for cocaine use disorder: evidence from preclinical research.

Authors:  Ewa Galaj; Briana Hempel; Allamar Moore; Benjamin Klein; Guo-Hua Bi; Eliot L Gardner; Herbert H Seltzman; Zheng-Xiong Xi
Journal:  Transl Psychiatry       Date:  2022-07-18       Impact factor: 7.989

2.  Cannabinoid CB2 receptors are expressed in glutamate neurons in the red nucleus and functionally modulate motor behavior in mice.

Authors:  Hai-Ying Zhang; Hui Shen; Ming Gao; Zegang Ma; Briana J Hempel; Guo-Hua Bi; Eliot L Gardner; Jie Wu; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2021-03-28       Impact factor: 5.250

3.  Targeting Endocannabinoid Signaling in the Lateral Habenula as an Intervention to Prevent Mental Illnesses Following Early Life Stress: A Perspective.

Authors:  Ryan D Shepard; Fereshteh S Nugent
Journal:  Front Synaptic Neurosci       Date:  2021-05-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.